Cargando…

Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms

Immune responses play a key role in the pathogenesis and progression of myeloproliferative neoplasms (MPN) and age-related macular degeneration (AMD). Recent studies suggested using MPNs as a “Human Inflammation Model” of drusen development and previous results showed interleukin-4 (IL-4) dysregulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotfredsen, Kathrine, Liisborg, Charlotte, Skov, Vibe, Kjær, Lasse, Hasselbalch, Hans Carl, Sørensen, Torben Lykke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008625/
https://www.ncbi.nlm.nih.gov/pubmed/36906669
http://dx.doi.org/10.1038/s41598-023-31078-w
_version_ 1784905796670193664
author Gotfredsen, Kathrine
Liisborg, Charlotte
Skov, Vibe
Kjær, Lasse
Hasselbalch, Hans Carl
Sørensen, Torben Lykke
author_facet Gotfredsen, Kathrine
Liisborg, Charlotte
Skov, Vibe
Kjær, Lasse
Hasselbalch, Hans Carl
Sørensen, Torben Lykke
author_sort Gotfredsen, Kathrine
collection PubMed
description Immune responses play a key role in the pathogenesis and progression of myeloproliferative neoplasms (MPN) and age-related macular degeneration (AMD). Recent studies suggested using MPNs as a “Human Inflammation Model” of drusen development and previous results showed interleukin-4 (IL-4) dysregulation in MPN and AMD. IL-4, IL-13 and IL-33 are all cytokines involved in the type 2 inflammatory response. This study investigated the cytokine levels of IL-4, IL-13 and IL-33 in serum of MPN and AMD patients. This cross-sectional study included 35 patients with MPN with drusen (MPNd) and 27 with MPN and normal retinas (MPNn), 28 patients with intermediate AMD (iAMD) and 29 with neovascular AMD (nAMD). With immunoassays, we quantified and compared levels of IL-4, IL-13 and IL-33 in serum between the groups. The study was conducted at Zealand University Hospital, Roskilde, Denmark, between July 2018 and November 2020. The serum levels of IL-4 were significantly higher in the MPNd group than in the MPNn group (p = 0.003). In regard to IL-33, the difference between MPNd and MPNn was not significant (p = 0.069), however, when subdivided into subgroups, a significant difference was found between polycythemia vera patients with drusen and those without drusen (p = 0.005). We found no IL-13 difference between the MPNd and MPNn groups. Our data didn’t show any significant IL-4 or IL-13 serum level difference between the MPNd and iAMD groups but in regard to IL-33, data recorded a significant serum level difference between the two groups. There was no statistically significant difference between the MPNn, iAMD and nAMD groups in levels of IL-4, IL-13 and IL-33. These findings suggested that the serum levels of IL-4 and IL-33 might play a role in drusen development in MPN patients. The results might represent the type 2 inflammatory arm of the disease. The findings support the association between chronic inflammation and drusen.
format Online
Article
Text
id pubmed-10008625
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100086252023-03-13 Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms Gotfredsen, Kathrine Liisborg, Charlotte Skov, Vibe Kjær, Lasse Hasselbalch, Hans Carl Sørensen, Torben Lykke Sci Rep Article Immune responses play a key role in the pathogenesis and progression of myeloproliferative neoplasms (MPN) and age-related macular degeneration (AMD). Recent studies suggested using MPNs as a “Human Inflammation Model” of drusen development and previous results showed interleukin-4 (IL-4) dysregulation in MPN and AMD. IL-4, IL-13 and IL-33 are all cytokines involved in the type 2 inflammatory response. This study investigated the cytokine levels of IL-4, IL-13 and IL-33 in serum of MPN and AMD patients. This cross-sectional study included 35 patients with MPN with drusen (MPNd) and 27 with MPN and normal retinas (MPNn), 28 patients with intermediate AMD (iAMD) and 29 with neovascular AMD (nAMD). With immunoassays, we quantified and compared levels of IL-4, IL-13 and IL-33 in serum between the groups. The study was conducted at Zealand University Hospital, Roskilde, Denmark, between July 2018 and November 2020. The serum levels of IL-4 were significantly higher in the MPNd group than in the MPNn group (p = 0.003). In regard to IL-33, the difference between MPNd and MPNn was not significant (p = 0.069), however, when subdivided into subgroups, a significant difference was found between polycythemia vera patients with drusen and those without drusen (p = 0.005). We found no IL-13 difference between the MPNd and MPNn groups. Our data didn’t show any significant IL-4 or IL-13 serum level difference between the MPNd and iAMD groups but in regard to IL-33, data recorded a significant serum level difference between the two groups. There was no statistically significant difference between the MPNn, iAMD and nAMD groups in levels of IL-4, IL-13 and IL-33. These findings suggested that the serum levels of IL-4 and IL-33 might play a role in drusen development in MPN patients. The results might represent the type 2 inflammatory arm of the disease. The findings support the association between chronic inflammation and drusen. Nature Publishing Group UK 2023-03-11 /pmc/articles/PMC10008625/ /pubmed/36906669 http://dx.doi.org/10.1038/s41598-023-31078-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Gotfredsen, Kathrine
Liisborg, Charlotte
Skov, Vibe
Kjær, Lasse
Hasselbalch, Hans Carl
Sørensen, Torben Lykke
Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
title Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
title_full Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
title_fullStr Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
title_full_unstemmed Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
title_short Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
title_sort serum levels of il-4, il-13 and il-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008625/
https://www.ncbi.nlm.nih.gov/pubmed/36906669
http://dx.doi.org/10.1038/s41598-023-31078-w
work_keys_str_mv AT gotfredsenkathrine serumlevelsofil4il13andil33inpatientswithagerelatedmaculardegenerationandmyeloproliferativeneoplasms
AT liisborgcharlotte serumlevelsofil4il13andil33inpatientswithagerelatedmaculardegenerationandmyeloproliferativeneoplasms
AT skovvibe serumlevelsofil4il13andil33inpatientswithagerelatedmaculardegenerationandmyeloproliferativeneoplasms
AT kjærlasse serumlevelsofil4il13andil33inpatientswithagerelatedmaculardegenerationandmyeloproliferativeneoplasms
AT hasselbalchhanscarl serumlevelsofil4il13andil33inpatientswithagerelatedmaculardegenerationandmyeloproliferativeneoplasms
AT sørensentorbenlykke serumlevelsofil4il13andil33inpatientswithagerelatedmaculardegenerationandmyeloproliferativeneoplasms